Clinical DevelopmentManagement confirmed 14 molecules from their pipeline are in the clinic and 95 initiated programs, highlighting active development efforts.

Financial StabilityStrong liquidity provides a runway of over three years and a key opportunity to expand the pipeline and partnership portfolio.

Strategic PartnershipsABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.

Bears Say

Financial PerformanceAbCellera's financial results for the third quarter fell below estimates, with significant earnings per share miss attributed to a substantial non-cash R&D impairment charge.

Future Revenue ConcernsAnalysts have reduced projections for future research fees and milestones due to limited visibility, suggesting potential challenges in revenue growth.

Revenue DeclineThe company's third-quarter revenue of $6.5 million did not meet expectations, and no new milestones were achieved during this period.

---

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

43.39% Insiders

0.41% Mutual Funds

22.67% Other Institutional Investors

32.49% Public Companies and

Individual Investors

Detailed Ownership Overview >

8QQ FAQ

What was AbCellera Biologics’s price range in the past 12 months?

AbCellera Biologics lowest stock price was €2.16 and its highest was €5.43 in the past 12 months.

What is AbCellera Biologics’s market cap?

Currently, no data Available

When is AbCellera Biologics’s upcoming earnings report date?

AbCellera Biologics’s upcoming earnings report date is Feb 25, 2025 which is in 65 days.

How were AbCellera Biologics’s earnings last quarter?

AbCellera Biologics released its earnings results on Nov 04, 2024. The company reported -€0.162 earnings per share for the quarter, missing the consensus estimate of -€0.118 by -€0.044.

Is AbCellera Biologics overvalued?

According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AbCellera Biologics pay dividends?

AbCellera Biologics does not currently pay dividends.

What is AbCellera Biologics’s EPS estimate?

AbCellera Biologics’s EPS estimate is -€0.13.

How many shares outstanding does AbCellera Biologics have?

AbCellera Biologics has 295,366,270 shares outstanding.

What happened to AbCellera Biologics’s price movement after its last earnings report?

AbCellera Biologics reported an EPS of -€0.162 in its last earnings report, missing expectations of -€0.118. Following the earnings report the stock price went down -8.257%.

Which hedge fund is a major shareholder of AbCellera Biologics?

Among the largest hedge funds holding AbCellera Biologics’s share is Baker Bros Advisors LP. It holds AbCellera Biologics’s shares valued at 72M.

---

AbCellera Biologics Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-15.55%

Trailing 12-Months

Asset Growth

-7.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.

---

8QQ Company Deck

---

8QQ Earnings Call

Q3 2024

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presents a mixed outlook. While AbCellera demonstrates strong liquidity and pipeline progress, the financials reveal increased losses and flat revenue growth. The transition to a clinical stage biotech and expansion in partnerships are positive, but financial challenges remain.Read More>

---

8QQ Revenue Breakdown

93.51% Research fees

3.94% Royalty revenue

2.55% Milestone payments

---

8QQ Stock 12 Month Forecast

Average Price Target

€7.96

▲(208.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","3.75":"€3.75","6.5":"€6.5","9.25":"€9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11.57838,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€11.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.96013625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.824325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.709,3.39126,4.07352,4.75578,5.43804,6.1203,6.80256,7.484819999999999,8.16708,8.84934,9.5316,10.21386,10.89612,{"y":11.57838,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.709,3.112933557692308,3.5168671153846156,3.920800673076923,4.324734230769231,4.7286677884615385,5.132601346153846,5.536534903846154,5.940468461538462,6.3444020192307695,6.748335576923077,7.152269134615384,7.556202692307693,{"y":7.96013625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.709,2.871717307692308,3.0344346153846153,3.197151923076923,3.359869230769231,3.5225865384615385,3.6853038461538463,3.8480211538461537,4.010738461538462,4.173455769230769,4.336173076923076,4.498890384615384,4.661607692307692,{"y":4.824325,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.914,"date":1702598400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.266,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.569,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.615,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.718,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.329,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.432,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.498,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.709,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

AbCellera Biologics

―

ALLO

Allogene Therapeutics

―

IMCR

Immunocore Holdings

―

MCRB

Seres Therapeutics

―

DNLI

Denali Therapeutics

―

Compare DE:8QQ Stocks >

Best Analysts Covering 8QQ

1 Year

Stephen WilleyStifel Nicolaus

1 Year Success Rate

2/11 ratings generated profit

1 Year Average Return

-34.39%

reiterated a buy rating 2 months ago

Copying Stephen Willey's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -34.39% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbCellera Biologics (8QQ) Stock Price & Analysis

8QQ Stock Chart & Stats

AbCellera Biologics News

Bulls Say, Bears Say

Financials

Options Prices

Ownership Overview

8QQ FAQ

AbCellera Biologics Stock Smart Score

Analyst Consensus

Blogger Sentiment

Technicals

Fundamentals

Company Description

AbCellera Biologics

8QQ Company Deck

8QQ Earnings Call

8QQ Revenue Breakdown

8QQ Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering 8QQ

Become an Expert with TipRanks Premium